𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CD8α is an activation marker for a subset of peripheral CD4 T cells

✍ Scribed by Emma Kenny; Don Mason; Abdelhadi Saoudi; Ana Pombo; Francisco Ramírez

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
296 KB
Volume
34
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Identification of an enriched CD4+ CD8α+
Identification of an enriched CD4+ CD8α++ CD8β+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma
✍ Ludwig E. Van den Hove; Stefaan W. Van Gool; Hein Van Poppel; Luc Baert; Lieve C 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 113 KB 👁 1 views

Three-color immunofluorescence flow-cytometric analysis of freshly isolated tumor-infiltrating lymphocytes (TIL) from patients with primary renal cell carcinoma (RCC) revealed a unique, not previously described TIL subset with a CD3+ CD4+ CD8alpha++ CD8beta+ phenotype. This subset represented at lea

Importance of the CD3 marker for evaluat
Importance of the CD3 marker for evaluating changes in rhesus macaque CD4/CD8 T-cell ratios
✍ Marta Dykhuizen; Jennifer Ceman; Jacque Mitchen; Maria Zayas; Alex MacDougall; J 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

Background: Until recently, there were no CD3 antibodies that crossreacted with rhesus macaque T cells. Consequently, studies relying on CD8 counts or CD4/CD8 ratios enumerated this subpopulation on the basis of CD8ϩ or CD8brightϩ staining. We used a rhesus-specific, anti-CD3 antibody to better defi

NKG2A is a marker for acquisition of reg
NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody
✍ Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C. Herold 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

## Abstract Treatment with anti‐CD3 mAb modulates immune responses that cause type 1 diabetes and other diseases. CD8^+^ Tregs can be induced in vitro and in vivo by mAb. However, 1/3 of patients do not respond to drug therapy and in an equal proportion, anti‐CD3 mAb does not induce Tregs in vitro.